ANUH PHARMA LIMITED
ANUHPHR · General/Diversified · NSE
₹76
Current Market Price
Fair Value (DCF)
₹74
Discount to FV
-1.9%
Updated just now
YieldIQ Score
55/100
Piotroski F-Score
5/9
Economic Moat
Narrow
Confidence
48%
ROE
11.7%
Debt/Equity
0.00
WACC
11.1%
Market Cap
₹760.40 Cr
Quality & Valuation
Neutral model outputs — no recommendations.
ROCE
18.8%
Return on capital employed
EV / EBITDA
10.6×
Enterprise multiple
Debt / EBITDA
0.0×
Leverage vs earnings
Interest Coverage
99.4×
EBIT covers interest
Current Ratio
2.11×
Short-term liquidity
Asset Turnover
1.52×
Revenue per ₹ of assets
Revenue CAGR (3Y)
13.5%
3-year revenue growth
Revenue CAGR (5Y)
—
5-year revenue growth
DCF Scenario Analysis
vs CMP ₹75.87
Bear case
Discount -67.4%
Base case
Discount -1.9%
Bull case
Discount +19.1%
Ratio Trends
ANUHPHR · last 5 annual periods
ROE
11.7%
ROCE
18.8%
Operating Margin
—
Debt / Equity
0.00×
PE
—
EV / EBITDA
—
Historical Financials
ANUHPHR · Annual, last 5 years· amounts in ₹Cr unless noted
| Metric | 2022 yfinance | 2023 yfinance | 2024 yfinance | 2025 yfinance | 2026 yfinance | CAGR |
|---|---|---|---|---|---|---|
| Revenue | ₹487 Cr | ₹527 Cr | ₹647 Cr | ₹662 Cr | ₹772 Cr | +12.2% |
| EBITDA | ₹52.0 Cr | ₹57.4 Cr | ₹87.2 Cr | ₹70.4 Cr | ₹66.1 Cr | +6.2% |
| EBIT | ₹40.1 Cr | ₹47.7 Cr | ₹78.7 Cr | ₹61.6 Cr | — | +11.4% |
| PAT | ₹30.6 Cr | ₹36.2 Cr | ₹60.1 Cr | ₹47.4 Cr | ₹41.0 Cr | +7.7% |
| EPS (diluted) | ₹3.05 | ₹3.61 | ₹5.99 | ₹4.72 | — | +11.6% |
| CFO | ₹28.9 Cr | ₹53.9 Cr | ₹12.9 Cr | ₹37.1 Cr | ₹-3.0 Cr | — |
| CapEx | ₹-1.6 Cr | ₹-1.6 Cr | ₹-5.0 Cr | ₹-20.1 Cr | ₹-7.9 Cr | — |
| FCF | ₹27.2 Cr | ₹52.4 Cr | ₹7.9 Cr | ₹17.0 Cr | ₹-10.9 Cr | — |
| Total Assets | ₹347 Cr | ₹405 Cr | ₹446 Cr | ₹507 Cr | ₹557 Cr | +12.6% |
| Total Debt | ₹4.2 Cr | ₹0.9 Cr | ₹2.7 Cr | ₹10.9 Cr | ₹0.1 Cr | -65.7% |
| Shareholders' Equity | ₹214 Cr | ₹241 Cr | ₹291 Cr | ₹326 Cr | ₹352 Cr | +13.3% |
CAGR computed across the visible window. Signs reverse if start value is zero or negative.
Peer Comparison
ANUHPHR vs 5 closest peers by market-cap band
| Peer | MoS | Score | Verdict | ROE | PE |
|---|---|---|---|---|---|
AHCL AHCL | — | — | Pending | 25.5% | — |
SIGACHI SIGACHI | — | — | Pending | 11.3% | — |
 KILITCH KILITCH | — | — | Pending | 10.8% | — |
ZIMLAB ZIMLAB | — | — | Pending | 4.8% | — |
AMANTA AMANTA | — | — | Pending | 6.8% | — |
Click a ticker to view its fair-value analysis.
Dividend History
1 ex-dividend event on file. Source: NSE corporate-actions feed.
Total paid (5Y)
₹1.50/sh
Last payout
2025-08-14
₹1.50
Peak payout
₹1.50
Trailing yield
1.98%
Amounts parsed from NSE subject lines. Percent-of-face-value declarations are converted using the per-ticker face value (defaults to ₹10).
AI Analysis Summary
Model-generated description of metrics. Not investment advice. ANUH PHARMA LIMITED (ANUHPHR.NS) trades at 75.87 vs a model fair value of 74.42, a gap of -1.9%. Piotroski F-score: 5/9. Moat label: Narr...
Read full AI analysis →Reverse DCF
Market-implied growth
What FCF growth is priced in →
Risk Analysis
Volatility & drawdown
Risk profile of ANUHPHR →
DuPont
ROE decomposition
Why ROE is what it is →
Technicals
RSI, MACD, MAs
Reference indicators →
News & Filings
Recent activity
BSE filings + news for ANUHPHR →
Compare
Head-to-head with peers
Compare ANUHPHR side by side →
Run Full Interactive Analysis
Interactive DCF sliders, sensitivity heatmap, peer comparison, and more.
Analyse ANUHPHRNow →Model estimates using publicly available data. Not investment advice. YieldIQ is not registered with SEBI as an investment adviser or research analyst. Past performance does not guarantee future results.